Hangzhou Tianji Jishi Biotechnology Co., Ltd.

Main research objectives: 1) Quantitative analysis of the total radioactivity in excreta after a single oral administration of [14C]TJ0113 in healthy male subjects, to obtain the total recovery rate of human radioactivity, excretion data and main excretion pathways; 2) Quantitative analysis of the total radioactivity in whole blood and plasma after a single oral administration of [14C]TJ0113 in healthy male subjects, to obtain the pharmacokinetic parameters of total radioactivity in whole blood (if applicable) and plasma, and to investigate the distribution of total radioactivity in whole blood and plasma; 3) Quantitative analysis of the radioactive metabolite profiles in human plasma, urine and feces after a single oral administration of [14C]TJ0113 in healthy male subjects, to identify the main metabolites, and to determine the metabolism and elimination pathways of TJ0113 in the human body. Secondary study objectives: 1) To quantitatively analyze the concentration of TJ0113 and its metabolites (if applicable) in plasma using a validated LC-MS/MS method and obtain the pharmacokinetic parameters of TJ0113 and its metabolites (if applicable) in plasma; 2) To observe the safety of [14C]TJ0113 after a single oral administration in healthy male subjects.